Soligenix Inc (SNGX)

12:41 PM

Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView

12:41 PM

Mar 04, 2026

SNGX Earnings History & Surprises | EPS & Revenue Results | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill

Mar 04, 2026

Mar 03, 2026

SNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Mar 02, 2026

Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behcet Disease - Digital Journal

Mar 02, 2026

Mar 02, 2026

Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - Digital Journal

Mar 02, 2026

Mar 02, 2026

Soligenix (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology - Digital Journal

Mar 02, 2026

Feb 27, 2026

SNGX Should I Buy - Intellectia AI

Feb 27, 2026

Feb 26, 2026

Soligenix receives positive EMA opinion for orphan drug status - Investing.com Australia

Feb 26, 2026

Feb 26, 2026

Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA). - Bitget

Feb 26, 2026

Feb 26, 2026

Soligenix receives positive EMA opinion for orphan drug status By Investing.com - Investing.com UK

Feb 26, 2026

Feb 26, 2026

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - Barchart.com

Feb 26, 2026

Feb 24, 2026

SNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 24, 2026

Feb 24, 2026

Growth Value: Is Soligenix Inc a speculative investmentOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn

Feb 24, 2026

Feb 24, 2026

Soligenix to Present at BIO Investment Summit - Intellectia AI

Feb 24, 2026

Feb 24, 2026

Soligenix to Present at BIO Investment & Growth Summit - Barchart.com

Feb 24, 2026

Feb 24, 2026

Soligenix CEO to Present at BIO Investment Summit Amid Key Clinical Developments - citybuzz -

Feb 24, 2026

Feb 23, 2026

SNGX PE Ratio & Valuation, Is SNGX Overvalued - Intellectia AI

Feb 23, 2026

Feb 20, 2026

Will Soligenix Inc. face regulatory challenges2025 Stock Rankings & Proven Capital Preservation Methods - mfd.ru

Feb 20, 2026

Feb 19, 2026

Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI

Feb 19, 2026

Feb 17, 2026

Armistice Capital and Steven Boyd report 4.99% stake in Soligenix (SNGX) - Stock Titan

Feb 17, 2026

Feb 17, 2026

Why Soligenix Inc. stock is favored by top institutions2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru

Feb 17, 2026

Feb 14, 2026

Soligenix, Inc. Announces Adjournment of Annual Meeting, Informa - GuruFocus

Feb 14, 2026

Feb 14, 2026

Will Soligenix Inc. stock split attract more investors2025 Geopolitical Influence & AI Forecasted Stock Moves - mfd.ru

Feb 14, 2026

Feb 13, 2026

Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX) - The Globe and Mail

Feb 13, 2026

Feb 12, 2026

Soligenix Provides Shareholder Update on Rare Disease Pipeline - TipRanks

Feb 12, 2026

Feb 12, 2026

Will Soligenix Inc. (DOA0) stock beat international competitionJuly 2025 Intraday Action & Stepwise Trade Execution Plans - mfd.ru

Feb 12, 2026

Feb 12, 2026

Soligenix (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options - Digital Journal

Feb 12, 2026

Feb 12, 2026

Soligenix Details Recent Progress and Upcoming Milestones - Morningstar

Feb 12, 2026

Feb 09, 2026

Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal

Feb 09, 2026

Feb 09, 2026

Soligenix’s (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - The Globe and Mail

Feb 09, 2026

Feb 08, 2026

Exit Recap: Is Soligenix Inc a speculative investment2025 Short Interest & Weekly Top Stock Performers List - baoquankhu1.vn

Feb 08, 2026

Feb 05, 2026

Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5% - Defense World

Feb 05, 2026

Feb 03, 2026

Soligenix (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer - The Globe and Mail

Feb 03, 2026

Feb 02, 2026

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape - The Globe and Mail

Feb 02, 2026

Jan 30, 2026

Soligenix (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) - Digital Journal

Jan 30, 2026

Jan 29, 2026

Soligenix Advances Novel Visible Light Therapy for Challenging Cutaneous T-cell Lymphoma - citybuzz -

Jan 29, 2026

Jan 29, 2026

Soligenix's HyBryte Therapy Shows Promise for Early-Stage Cutaneous T-Cell Lymphoma Treatment - citybuzz -

Jan 29, 2026

Jan 29, 2026

Soligenix Advances Novel Visible Light Therapy for Early-Stage Cutaneous T-Cell Lymphoma - MEXC

Jan 29, 2026

Jan 26, 2026

RiVax(R) Positions Soligenix (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts - Digital Journal

Jan 26, 2026

Jan 24, 2026

Soligenix Establishes At-The-Market Equity Offering Program - The Globe and Mail

Jan 24, 2026

Jan 23, 2026

Soligenix’s RiVax Vaccine Advances as Ricin Threats Highlight Biodefense Needs - citybuzz -

Jan 23, 2026

Jan 23, 2026

Soligenix enters sales agreement with Rodman - marketscreener.com

Jan 23, 2026

Jan 23, 2026

Soligenix Inc Enters Sales Agreement With Rodman - TradingView

Jan 23, 2026

Jan 23, 2026

Soligenix Enters At Market Issuance Sales Agreement - TradingView

Jan 23, 2026

Jan 20, 2026

Soligenix (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease - Digital Journal

Jan 20, 2026

Jan 18, 2026

Soligenix’s SGX945 in Behcet’s disease published in Rheumatology (Oxford) - MSN

Jan 18, 2026

Jan 16, 2026

Soligenix Reports Positive Phase 2 Results for Behçet’s Disease Treatment - citybuzz -

Jan 16, 2026